SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat).
In the Exhibition section, we will introduce our drug efficacy evaluation study services using our original MASH (NASH)-hepatocarcinoma model, STAM™ mouse, as well as other pathological mouse models related to inflammation and fibrosis in various organs and histopathological analysis services.
It is possible to see the experience of STAM™ mice, which have advanced more than 15 compounds into clinical trials so far, especially in this exhibition,
Drug efficacy data on Rezdiffra (resmetirom), the first FDA-approved drug for the treatment of MASH
MASH-derived hepatocarcinoma drug candidate (currently in Phase 3)
The following information is available for the development of drugs for MASH and HCC that occurs after the onset of MASH.
If you are interested in learning more about our services as a CRO or the STAM™ mice, please feel free to contact us in person at the event!
Hope to see you all at The 110th General Meeting of the Japanese Society of Gastroenterology in a few weeks!
About The 110th General Meeting of the Japanese Society of Gastroenterology
■Date: May 9 (Thu) -11 (Sat), 2024
■Venue: ASTY Tokushima （Tokushima）
■Access: https://www.asty-tokushima.jp/translate/en/
■Website: https://site.convention.co.jp/110jsge/general-information/
■Services: Pharmacology Testing Services / Histology Services